Stockscreener 앱 받기
9.02
3.09%
0.27
시간 외 거래:
9.02
전일 마감가:
$8.75
열려 있는:
$8.66
하루 거래량:
836.02K
Relative Volume:
1.55
시가총액:
$487.91M
수익:
$2.81M
순이익/손실:
$-97.34M
주가수익비율:
-5.7089
EPS:
-1.58
순현금흐름:
$-91.47M
1주 성능:
-6.53%
1개월 성능:
-2.17%
6개월 성능:
+60.50%
1년 성능:
+181.00%
1일 변동 폭
$8.48
$9.47
1주일 범위
$8.29
$10.11
52주 변동 폭
$2.315
$10.11
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
FULC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
9.02 | 473.30M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2023-09-25 | 개시 | Goldman | Neutral |
| 2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - The Manila Times
Fulcrum Therapeutics to Present Phase 1b PIONEER Trial Data on Pociredir for Sickle Cell Disease at ASH 2025 - Quiver Quantitative
Will Fulcrum Therapeutics Inc. stock gain from strong economyJuly 2025 WrapUp & Reliable Entry Point Trade Alerts - newser.com
Will Fulcrum Therapeutics Inc. stock beat EPS estimatesTrade Risk Summary & Safe Entry Momentum Tips - newser.com
Can Fulcrum Therapeutics Inc. stock resist sector downturns2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
Multi asset correlation models including Fulcrum Therapeutics Inc.July 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
How Fulcrum Therapeutics Inc. stock responds to policy changesWeekly Risk Report & Capital Efficiency Focused Strategies - newser.com
Momentum divergence signals in Fulcrum Therapeutics Inc. chartQuarterly Investment Review & Reliable Volume Spike Alerts - newser.com
Statistical indicators supporting Fulcrum Therapeutics Inc.’s strengthMarket Growth Review & Pattern Based Trade Signal System - newser.com
How to track smart money flows in Fulcrum Therapeutics Inc.Watch List & Free Risk Controlled Daily Trade Plans - newser.com
What is Leerink Partnrs' Estimate for FULC FY2025 Earnings? - MarketBeat
FY2025 EPS Forecast for Fulcrum Therapeutics Cut by Analyst - MarketBeat
FY2025 EPS Estimate for Fulcrum Therapeutics Cut by Analyst - MarketBeat
How to build a dashboard for Fulcrum Therapeutics Inc. stockBreakout Watch & Verified High Yield Trade Plans - newser.com
Why Fulcrum Therapeutics Inc. stock is in analyst buy zone2025 Short Interest & Fast Gaining Stock Reports - newser.com
Fulcrum Therapeutics Inc. stock outlook for YEAR2025 Macro Impact & Short-Term High Return Strategies - newser.com
Will Fulcrum Therapeutics Inc. continue its uptrendPortfolio Value Summary & High Accuracy Trade Signal Alerts - newser.com
Published on: 2025-11-02 22:53:39 - newser.com
Why Fulcrum Therapeutics Inc. stock remains on buy listsWeekly Trade Recap & Fast Entry High Yield Tips - newser.com
Signal strength of Fulcrum Therapeutics Inc. stock in tech scannersJuly 2025 Decliners & Fast Entry Momentum Alerts - newser.com
Fulcrum Therapeutics Inc. stock volume spike explainedMarket Risk Summary & Capital Protection Trade Alerts - newser.com
What risks investors should watch in Fulcrum Therapeutics Inc. stockMarket Trend Report & Fast Momentum Stock Entry Tips - newser.com
Tick level data insight on Fulcrum Therapeutics Inc. volatilityMarket Movement Recap & Technical Entry and Exit Tips - newser.com
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen - MarketBeat
What is HC Wainwright's Estimate for FULC Q1 Earnings? - MarketBeat
How institutional buying supports Fulcrum Therapeutics Inc. stockJuly 2025 Earnings & Fast Entry and Exit Trade Plans - newser.com
Fulcrum Therapeutics (NASDAQ:FULC) Price Target Raised to $7.00 - MarketBeat
Published on: 2025-10-31 05:47:11 - newser.com
Is Fulcrum Therapeutics Inc. trending in predictive chart modelsBreakout Watch & High Return Trade Guides - newser.com
How sustainable is Fulcrum Therapeutics Inc. stock dividend payoutMarket Volume Report & Accurate Intraday Trade Tips - newser.com
How to forecast Fulcrum Therapeutics Inc. trends using time series - newser.com
Fulcrum Therapeutics Inc (FULC) Q3 2025 Earnings Call Highlights: Promising Advances in Sickle ... By GuruFocus - Investing.com Canada
Fulcrum Therapeutics Inc (FULC) Q3 2025 Earnings Call Highlights - GuruFocus
Fulcrum Therapeutics (FULC) Price Target Increased by 10.32% to 12.46 - MSN
RBC Capital Updates Fulcrum Therapeutics (FULC) Price Target Ami - GuruFocus
Fulcrum Therapeutics (NASDAQ:FULC) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Piper Sandler Raises Price Target on Fulcrum Therapeutics (FULC) - GuruFocus
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2025 Earnings Call Transcript - Insider Monkey
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.35%
자본화:
|
볼륨(24시간):